Zobrazeno 1 - 10
of 6 715
pro vyhledávání: '"Lei L. Chen"'
Autor:
Lei L Chen, Jing Zhu, Jonathan Schumacher, Chongjuan Wei, Latha Ramdas, Victor G Prieto, Arnie Jimenez, Marco A Velasco, Sheryl R Tripp, Robert H I Andtbacka, Launce Gouw, George M Rodgers, Liansheng Zhang, Benjamin K Chan, Pamela B Cassidy, Robert S Benjamin, Sancy A Leachman, Marsha L Frazier
Publikováno v:
PLoS ONE, Vol 12, Iss 9, p e0184154 (2017)
We demonstrate that SCF-KIT signaling induces synthesis and secretion of endothelin-3 (ET3) in human umbilical vein endothelial cells and melanoma cells in vitro, gastrointestinal stromal tumors, human sun-exposed skin, and myenteric plexus of human
Externí odkaz:
https://doaj.org/article/46dfaee1e3fc43939d5e87e4ff5f3493
Autor:
Launce Gouw, Sancy A. Leachman, Marco A. De Velasco, Jonathan A. Schumacher, Chongjuan Wei, Robert S. Benjamin, Marsha L. Frazier, Victor G. Prieto, George M. Rodgers, Lei L. Chen, Robert H.I. Andtbacka, Latha Ramdas, Benjamin K. Chan, Jing Zhu, Sheryl R. Tripp, Arnie Jimenez, Pamela B. Cassidy, Liansheng Zhang
Publikováno v:
PLoS ONE
PLoS ONE, Vol 12, Iss 9, p e0184154 (2017)
PLoS ONE, Vol 12, Iss 9, p e0184154 (2017)
We demonstrate that SCF-KIT signaling induces synthesis and secretion of endothelin-3 (ET3) in human umbilical vein endothelial cells and melanoma cells in vitro, gastrointestinal stromal tumors, human sun-exposed skin, and myenteric plexus of human
Publikováno v:
OncoImmunology. 1:773-776
Imatinib revolutionized gastrointestinal stromal tumor (GIST) treatment but median-progression-free-survival of unresectable/metastatic disease is < 2 y. B-RAFV600-mutated-melanoma responds to vemurafenib dramatically but median-progression-free-surv
Autor:
A. K. Raymond, Jonathan C. Trent, Kelly K. Hunt, Lei L. Chen, John H. Ward, Kimberly A. Jones, Joseph A. Holden, Marsha L. Frazier, R. Lor Randall, Robert H.I. Andtbacka, Courtney L. Scaife, Haesun Choi, Jing Zhu, Wei Zhang, Elsie F. Wu, Robert S. Benjamin, Victor G. Prieto
Publikováno v:
Modern Pathology. 21:826-836
Activating mutation in KIT or platelet-derived growth factor-alpha can lead to gastrointestinal stromal tumors (GISTs). Eighty-four cases from two institutes were analyzed. Of them, 62 (74%) harbored KIT mutations, 7 of which are previously unreporte
Autor:
Chuslip Charnsangavej, Robert S. Benjamin, Michael A. Burgess, Lei L. Chen, Haesun Choi, Silvana de Castro Faria, Donald A. Podoloff, Homer A. Macapinlac, Shreyaskumar Patel
Publikováno v:
Journal of Clinical Oncology. 25:1753-1759
Purpose Response Evaluation Criteria in Solid Tumors (RECIST) are insensitive in evaluating gastrointestinal stromal tumors (GISTs) treated with imatinib. This study evaluates whether computed tomography (CT) findings of GIST after imatinib treatment
Autor:
Shreyaskumar Patel, Peter W.T. Pisters, Janice N. Cormier, Lei L. Chen, Raphael E. Pollock, Robert S. Benjamin, Yan Xing, Stephan A. Vorburger, Matthew T. Ballo, Kelly K. Hunt, Gregory E. Lakin, Michael A. Burgess, Jonathan C. Trent, Barry W. Feig
Publikováno v:
Cancer. 104:2682-2688
Autor:
Jonathan C. Trent, Kimberly Hayes, A. K. Raymond, Victor G. Prieto, Marco A. De Velasco, Shreyaskumar Patel, Elsie F. Wu, Robert S. Benjamin, Michael A. Burgess, Marsha L. Frazier, Walter N. Hittelman, Barry W. Feig, Caroline O. Oyedeji, Lei L. Chen, Wei Zhang, Raphael E. Pollock, Homer A. Macapinlac, Kelly K. Hunt, Gregory N. Fuller, Haesun Choi, Latha Ramdas
Publikováno v:
Cancer Research. 64:5913-5919
KIT gain of function mutations play an important role in the pathogenesis of gastrointestinal stromal tumors (GISTs). Imatinib is a selective tyrosine kinase inhibitor of ABL, platelet-derived growth factor receptor (PDGFR), and KIT and represents a
Autor:
Shreyaskumar R. Patel, Michael A. Burgess, Nicholas Papadopolous, Robert S. Benjamin, R N Jennifer Beach, Lei L. Chen, Jonathan C. Trent
Publikováno v:
Cancer. 98:2693-2699
BACKGROUND. The authors conducted a two-arm Phase II study of temozolomide to determine its efficacy and toxicity in patients with soft tissue sarcomas (STSs) who had received, had refused, or were not eligible for standard chemotherapy with doxorubi
Autor:
A. Kevin Raymond, Kelly K. Hunt, Robert S. Benjamin, Janice N. Cormier, Courtney L Scaife, Lei L. Chen, Raphael E. Pollock, Peter W.T. Pisters, Barry W. Feig, Shreyaskumar Patel, Michael A. Burgess, Jonathan C. Trent
Publikováno v:
The American Journal of Surgery. 186:665-669
Background Imatinib mesylate (Gleevec) is being studied as adjuvant chemotherapy for the treatment of c KIT + gastrointestinal stromal tumors (GISTs). Early reports using Gleevec for the treatment of unresectable GISTs have shown 50% to 60% partial r
Autor:
Thomas Ciesielski, Nelofar Shafi, Lei L. Chen, Nav.T. Singh, Valerie Synnott, Edward.L. Pesanti, Syed Bilgrami
Publikováno v:
Acta Haematologica. 93:101-104
Rare cases of low-grade lymphomas have been described in patients with human immunodeficiency virus (HIV) infection. However, this is the first reported case of mantle-cell lymphoma, a type of low-grade lymphoma, in a patient who also had HIV infecti